News and Views

The Official Blog of WhaleWisdom.com

Workday Inc. (WDAY) underperformed the S&P 500, seeing a loss of approximately 50% compared to the S&P 500’s loss of about 18% over the past year. Hedge funds were actively buying shares despite recent performance fluctuations, and the stock impressively rose to the top of the WhaleWisdom Heatmap in the third quarter of 2022.

Workday is a cloud-based human capital management (HCM), financial management, enterprise performance management (EPM), and student information system software, vendor. Its cloud-based software solutions offer organizations critical business solutions and analytics tools worldwide. HCM solutions provide talent management, performance management, compensation, and succession planning capabilities to help customers attract, develop, and retain their workforce. Financial Management solutions include automated processes that allow clients to divert their time and focus away from transaction processing and more on the big picture through data analytics. The company’s student information systems are designed to support students and leaders of educational institutions through flexible programs. EPM solutions include financial management, talent management, enterprise planning, and spend management. Workday brings in revenue from client subscriptions and software sales through a software-as-a-service (SaaS) delivery model.

Despite seeing stock volatility in the past year, the Coronavirus pandemic considerably impacted Workday. Government restrictions and corporate safety measures pushed workforces to remote and hybrid work schedules. Workday was able to capitalize on the shift to remote work and increase its corporate client subscriptions as more and more companies migrated to the cloud and needed applications to efficiently manage critical business operations such as payroll and human resources. Workday has invested in research and development and has made strategic acquisitions over the years to diversify and expand its offerings for a more resilient business model.

(WhaleWisdom)

Hedge Funds Are Buying

Workday has the attention of hedge fund managers, who were actively buying the stock in the third quarter. Hedge funds’ aggregate 13F shares held in the third quarter increased to about 63.7 million from 61.0 million, an increase of approximately 4.4%. Of the hedge funds, 47 created new positions, 80 added to an existing one, 28 exited, and 67 reduced their stakes. In contrast, institutions were selling, and aggregate holdings decreased mildly by about 0.7% to approximately 171.4 million from 172.4 million. The long-term 13F metrics between 2014 and 2022 suggest that despite Workday’s stock price volatility this year, it remains on a slow upward trend.

(WhaleWisdom)

Encouraging Multi-year Estimates

Analysts anticipate earnings will rise through 2024, with year-over-year increases in growth that could bring earnings to $4.45 per share by January 2024, up from a projected $3.39 for 2023. Revenue predictions are also favorable, with revenue expected to increase to about $7.4 billion by January 2024, up from an estimated $6.2 billion in January 2023.

(WhaleWisdom)

Analysts Adjust Ratings

Due to recent market volatility and macro conditions, analysts appear to be proceeding with caution. Analyst John DiFucci of Guggenheim Investments upgraded the firm’s rating on Workday to Neutral from Sell, viewing shares as fairly valued while noting that Workday has a challenge in meeting long-term targets for subscription revenue growth. Analyst Brian White of Monness, Crespi, Hardt & Co., Inc. downgraded Workday to a Neutral rating from a Buy, noting that the next year will be challenging as the economy grows weaker. White shared optimism that Workday will continue expanding its cloud platform’s reach.

Favorable Outlook Beyond 2022

While Workday’s growth has slowed, hedge funds are still buying shares, and earnings estimates through 2024 are encouraging. Demand for the company’s cloud-based solutions should continue to grow revenue, and the technology stock presents an attractive long-term investment.

Texas Instruments, Inc.’s (TXN) stock experienced a sharp decline over the past year but managed to outperform the S&P 500. It has been a tough year for the stock market, and Texas Instruments saw a decrease of approximately 9% compared to the S&P’s loss of about 18%. Hedge funds were actively selling the stock in the second quarter of 2022, though the stock’s value improved over the past month.

Texas Instruments is a technology company that designs and manufactures semiconductors and integrated circuits, selling them to electronics designers and manufacturers worldwide. The semiconductor industry has been highly impacted by inflation, Federal Reserve rate hikes, and supply-chain challenges, though demand for semiconductor chip technology remains strong.

The company’s business consists of two core operating segments, Analog and Embedded Processing, and Texas Instruments products are used across various industries. While some consumers initially think of Texas Instruments as the maker of scientific calculators required for high school and college math classes, Texas Instruments’ analog and embedded semiconductors are utilized in far more than education-based technology. Texas Instruments products are widely used in industrial, personal electronics, automotive, enterprise, and communications equipment markets. Manufacturers like Texas Instruments, who can support and meet the changing needs of artificial intelligence and Internet of Things (IoT) technologies, have opportunities for future growth in these markets.

(WhaleWisdom)

Hedge Funds and Institutions Trim Portfolios

Texas Instruments’ second-quarter activity included hedge funds selling. The aggregate 13F shares held by hedge funds decreased to about 128.5 million from 131.9 million, a change of approximately 2.6%. Of the hedge funds, 25 created new positions, 115 added to an existing one, 27 exited, and 123 reduced their stakes. Institutions also mildly decreased their aggregate holdings by about 0.8%, to approximately 758.0 million from 764.2 million.

(WhaleWisdom)

Earnings Decline Expected

Investors should prepare for the long game as analysts cut their earnings estimates for Texas Instruments. Earnings are expected to decrease to $8.00 by December 2023, down from an expected $9.52 for December 2022. Revenue is expected to decline to roughly $18.4 billion by December 2023, down from 20.0 billion in 2022. However, despite less than favorable earnings and revenue estimates through 2023, the long-term 13F metrics between 2005 and 2022 suggest that Texas Instrument’s investment potential remains strong.

(WhaleWisdom)

Analysts Cut Targets

Analyst Christopher Rolland of Susquehanna Financial Group reacted to the signs of a slowdown in demand in the semiconductor industry. He lowered the firm’s price target on Texas Instruments to $195 from $215, maintaining a Positive Rating on shares. While weaker demand in some markets is likely temporary, other analysts have followed suit in lowering price targets. Citi analyst Christopher Danely kept a Neutral rating on Texas Instruments and lowered the firm’s price target to $155. While Texas Instruments reported favorable third-quarter results, fourth-quarter guidance fell below consensus. Analyst John Vinh of KeyBanc Capital Markets lowered the firm’s price target on Texas Instruments to $210 from $220 and kept an Overweight rating on shares.

Favorable Long-Term Outlook

Market volatility and semiconductor manufacturing challenges have taken their toll on this technology stock. Understandably, analysts have lowered price targets as the earnings outlook through 2023 decreases. As Texas Instruments’ stock continues moving in a positive direction and demand for semiconductor chips becomes stronger, there is optimism for sales and earnings growth beyond 2023. Existing investors should hold onto this stock as it presents an excellent long-term investment opportunity.

Intel Corp. (INTC) underperformed the S&P 500, falling roughly 45% compared to the S&P 500’s loss of about 20% over the past year. Amidst challenging economic conditions, hedge funds were actively selling Intel’s shares.

Intel is a multinational technology company that designs, develops, and manufactures semiconductor computer products and technologies. The company operates through various segments, including the Client Computing Group, Data Center Group, Internet of Things Group, Non-volatile Memory Solutions Group, and Programmable Solutions Group.

Over the past five decades, Intel has evolved into a more data-centric company. While personal computer (PC) related products are still a significant part of its revenue stream, Intel continues to adapt, invest in research and development, and utilize strategic partnerships to enhance technologies and meet consumer demands. Intel has a lot of competition in the chipmaker market and is presently investing in its semiconductor manufacturing operations to improve the fabrication process. Much of the challenges Intel faced over the past year were experienced by the semiconductor industry overall, which has been impacted by high inflation, rising interest rates, and supply-chain delays.

(WhaleWisdom)

Mixed Actions from Hedge Funds and Institutions

Hedge funds were selling in the second quarter, with the aggregate 13F shares held by hedge funds lowered to about 337.8 million from 349.8 million, a change of approximately 3.4%. Of the hedge funds, 31 created new positions, 163 added to an existing position, 56 exited, and 148 reduced their position. In contrast to hedge funds, institutions increased their aggregate holdings by about 0.5% to approximately 2.50 billion from 2.49 million. The 13F metrics between 2005 and 2022 show that while funds have been on a steady upward trend, Intel’s stock price has taken a downturn over the past two years.

(WhaleWisdom)

Declining Forecast

Analysts are cutting their earnings estimates for Intel. Earnings are expected to decline in the coming year, decreasing to $1.26 by December 2023, down from an expected $2.05 for December 2022. Performance is expected to bring revenue to roughly $62.0 billion by late 2023, down from 63.6 billion in 2022.

(WhaleWisdom)

Price Targets Are Adjusted

Analysts appear to share a lukewarm view of the company based on ratings and declining price targets. Christopher Danely of Citi maintained a Neutral rating on Intel and lowered the firm’s price target on the company to $27 from $30. Baird & Co. analyst Tristan Gerra was encouraged by Intel’s earnings report and kept a Neutral rating on shares. Gerra lowered the firm’s price target on Intel to $34 from $40. Gus Richard of Northland Capital Markets held a $52 price target on Intel, and an Outperform rating. Richard expects to see improved performance by the second half of 2023.

Queue the Patient Investor

Analysts’ estimates for Intel include a decline in earnings and revenue through 2023. However, while forecasts for the year ahead may not be encouraging, investors should keep an eye on the stock and wait as its business turns around. Intel is still one of the largest chipmakers in the semiconductor industry and has been making strategic business decisions to improve its infrastructure and reduce costs. The stock has a better long-term outlook for patient investors.

Shares of Netflix Rebound Amid Renewed Growth

Posted on October 31st, 2022

Netflix, Inc. (NFLX) experienced a challenging year navigating 2022’s tumultuous market. Netflix had disappointing performance and faced strong competition. Fortunately, Netflix saw a mild rebound in October but continues to underperform the S&P 500. Netflix has fallen by approximately 60% compared to the S&P’s decline of about 12% as of October 27, 2022, over the past year. Hedge funds were actively selling the stock in the second quarter, though the stock rose on the WhaleWisdom Heatmap to a ranking of nine from sixteen.

Netflix is an entertainment services company that provides a subscription streaming service and has a production company that produces and co-produces streaming content. The company has over 200 million subscribers worldwide and brings in revenue primarily from subscriber fees, with a more recent focus on advertising. Netflix seeks to improve subscribership and revenue statistics by cracking down on customers’ password sharing. Their strategy involves monetizing the practice of account sharing by allowing subscribers to transfer profiles beyond their primary household and create sub-accounts for a smaller fee. Netflix is also launching an ad-supported membership option in twelve countries beginning in November 2022. For a lower subscription cost, customers can choose the ad-supported plan, which will apply targeted marketing capabilities for audiences based on factors such as the content they stream and the country they reside in.

(WhaleWisdom)

Hedge Funds and Institutions Sell

Hedge Funds adjusted their portfolios in the second quarter, and the aggregate 13F shares held decreased to approximately 70.8 million from 73.4 million, a slide of about 3.6%. Overall, 50 hedge funds created new positions, 139 added, 114 exited, and 99 reduced their holdings. Institutions also sold and lowered their holdings by about 3.3% to $333.7 million. The 13F metrics between 2005 and 2022 suggest that Netflix still has long-term investment potential.

(WhaleWisdom)

Encouraging Multi-year Estimates

Analysts anticipate earnings will rise through 2023, with year-over-year increases in growth that could bring earnings to $10.66 per share by December 2023, up from a projected $10.31 for 2022. Revenue predictions are also favorable, with revenue expected to increase to about $33.9 billion by 2023, up from an estimated $31.6 billion in December 2022.

(WhaleWisdom)

Analysts Are Encouraged by Improved Performance

Netflix saw growth once again in October, and analysts took notice. Pivotal Research Group analyst Jeffrey Wlodarczak raised the firm’s rating on the stock to a Buy from a Sell and set a price target of $375 on Netflix shares. Wlodarczak expressed optimism at Netflix’s ability to recoup revenue lost from customers’ password sharing and appeared cautious about the risk of customers downgrading subscription services in a recession. Analyst Satoshi Tanaka of Daiwa Capital raised their firm’s price target on Netflix to $330 from $226 following improved earnings and upgraded the stock to an Outperform rating from a prior Neutral rating projection. Oppenheimer & Co. analyst Jason Helfstein kept an Outperform rating on Netflix and raised the firm’s price target to $365 from $325. Helfstein was encouraged by Netflix’s strategy to identify shared accounts and push many account holders to ad-supported streaming subscriptions.

Better Days Beyond 2022

Netflix is beginning to rebound from this bearish market, and investors should be encouraged by analysts’ optimistic earnings and revenue estimates through December of 2023. While hedge funds sold in the second quarter, Netflix’s losses offer the opportunity to acquire the stock for less. Netflix continues to offer new streaming content and older TV and movie favorites to its customers. The streaming provider has developed strategies to launch ad-supported membership globally and recoup lost revenue from ad-sharing. Netflix has positioned itself well to adapt to changes in demand and draw investors’ attention.

UnitedHealth Group Inc. (UNH) stock slower has dropped over the past year, though the company significantly outperformed the S&P 500, rising by approximately 22% compared to the S&P’s loss of about 21% as of October 20, 2022. Hedge funds were selling, and the healthcare company landed on the WhaleWisdom HeatMap at a ranking of three.

UnitedHealth is a diversified healthcare and insurance company that offers healthcare products and insurance services. The company’s two core platforms include UnitedHealthcare, comprised of its health benefit plans and services, and OptumRx, a line of pharmacy care services and programs, including home delivery and clinical capabilities. UnitedHealth generates the bulk of its revenue from premiums on risk-based products, fees for services, the sale of healthcare products, and investments.

Rising expenses and temporary government mandates have impacted the healthcare industry throughout the Coronavirus pandemic. Health insurers’ medical costs and profits fluctuated from increased hospitalizations, restrictions on non-urgent and elective procedures, and inflation. However, United Health anticipates that these challenges and higher costs will ease in the coming year.

Hedge Funds Sell Shares

UnitedHealth saw hedge funds selling in the second quarter of 2022, with the aggregate 13F shares held lowered to approximately 143.5 million from 150.7 million, a change of roughly 4.8%. Of the hedge funds, 30 created new positions, 175 added their stakes, 48 exited, and 208 reduced their holdings. Institutions sold and decreased their aggregate holdings by a modest 0.2% to approximately 808.9 million from 810.8 million.

Favorable Revenue Estimates

Analysts expect to see earnings increasing through 2023, bringing earnings per share to $22.03 by December 2022 and $24.95 by December 2023. Estimates are also encouraging for revenue, with an anticipated rise by December 2022 to approximately $323.3 billion; this momentum may continue with revenue estimated at $352.1 billion by December 2023.

Analysts Respond to Strong Q3 Results

UnitedHealth exceeded Wall Street’s expectations in the third quarter, causing the company to raise its earnings outlook and many analysts to raise price targets. Deutsche Bank analyst George Hill kept a Buy rating on UnitedHealth’s shares and increased the firm’s price target to $615 from $569. RBC Capital Markets maintained an Outperform rating on the stock and raised its price target on UnitedHealth to $592 from $588. Raymond James lowered its price target on UnitedHealth to $615 while maintaining the company as a Strong Buy.

Optimistic Outlook

UnitedHealth’s performance over the past year demonstrates its ability to grow despite pandemic challenges and a volatile market. The healthcare industry has growth potential, and UnitedHealth’s products and services will likely see continued demand. Analysts’ encouraging earnings and revenue growth predictions through 2023 support UnitedHealth as a worthwhile investment opportunity.